Sept 2026 Quarterly Activities Report and Appendix 4C
Filed with ASX · · 12 pages · English
Summary by 6ix AI
Racura reported a strong cash balance, with the majority of expenditures directed towards research and development activities, positioning the company well for future commitments. The report also includes management commentary emphasizing the progress made in clinical programs and the company's financial stability.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Racura Oncology
- HARNESS-1 First Cohort Cleared
- Racura Presents CPACS Data at GCOS 2026
- Date of AGM & Closing Date for Director Nominations
- Appendix 3Y - Dr Daniel Tillett
- RC220 MYC-silencing data to be presented FCS 26 conference
Later from Racura Oncology
- Letter to Shareholders, Notice of AGM & Proxy Form
- Racura Presents Bisantrene MYC Data at FCS 2026
- Racura Successfully PK Bridges RC110 RC220
- Sheba Grants Ethics Approval for EMILI AML Trial
- EMILI Investor Webinar Nov 2026
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology